Premium
Potential COVID‐19 Therapeutic Agents and Vaccines: An Evidence‐Based Review
Author(s) -
Khani Elnaz,
Khiali Sajad,
EntezariMaleki Taher
Publication year - 2021
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.1822
Subject(s) - medicine , intensive care medicine , disease , pandemic , covid-19 , coronavirus , food and drug administration , authorization , drug , infectious disease (medical specialty) , pharmacology , virology , outbreak , computer security , computer science
Since the early days of 2020, the severe acute respiratory syndrome coronavirus 2 pandemic has become a global health concern. Currently, some therapies and vaccines have received US Food and Drug Administration approval or emergency use authorization for the management of coronavirus disease 2019. According to the pathophysiology of the disease, several medications have been evaluated in different clinical conditions of the disease. Evidence‐based reviewing and categorizing these medications can guide the clinicians to select the proper medications according to each patient's condition. Therefore, we performed this review to categorize the coronavirus disease 2019 potential therapeutics and vaccines.